Lung cancer is the deadliest form of cancer in terms of number of deaths in Sweden, yet a national screening program is still lacking. A new report from IHE - The Swedish Institute for Health Economics, commissioned by Vision Zero Cancer and AstraZeneca, shows that AI can reduce the resource need and costs for radiologists by approximately 80% and enable earlier detection.

The report has been developed as a part of IHE’s partnership in the VINNOVA-funded innovation milieu Test Bed Sweden Precision Health Cancer.

Together with Lif - de forskande läkemedelsföretagen, Business Sweden, Embassy of Sweden in Madrid, Spain, we arranged for the second consecutive year a special evening event during the ESMO congress.

Cancer is a global societal challenge. To meet it, we need to create better conditions for implementing new knowledge, new methods, and interventions. We need to think anew and adopt a holistic perspective on health. We need to collaborate in new ways between healthcare, industry, and civil society.

The development of precision medicine has been ongoing since the 1990s. From treatments for a few patients, we are today faced with the widespread introduction of precision medicine in new parts of healthcare.

On April 23rd-24th, Vision Zero Cancer/ SIR will be at the Nordic Precision Medicine Forum in Stockholm and organise a workshop on impact assessment frameworks for Precision Medicine implementation.

The lung cancer policy network speaks to Ebba Hallersjö Hult, Co-founder and Head of Vision Zero Cancer, a mission-oriented innovation hub coordinated by Stockholm School of Economics Institute for Research, Sweden.

Folkhälsodalen (The Public Health Valley) is a meeting place for decision-makers, professionals, industry, and researchers in public health, medicine, and healthcare. An initiative of Reform Society. The seminars are in Swedish.

House of Innovation in collaboration with the Department of Accounting at Stockholm School of Economics orgianizes two Workshops on Measuring Impact of Mission Driven Innovation Collaborations during this fall.

A Public-Private Partnership focusing on implementation of precision health in cancer in Sweden is under establishment. SweConnect will be project managed by Vision Zero Cancer in collaboration with Genomic Medicine Sweden (GMS).

Implementation of precision cancer medicine and economic evaluation for Health Technology Assessment (HTA) – what are the challenges and how do we address them?

The PRIME-ROSE kick-off took place in Oslo on September 19-20 and gathered around 70 participants from different partners across Europe.

Testbed Sweden Precision Cancer is attending the PRIME-ROSE kick-off in Oslo right now!

We are looking forward to participating at the Nordic Precision Cancer Medicine conference in Oslo during next week.

FOCU.SE is an initiative by Testbed Sweden Precision Health Cancer, founded by Vision Zero Cancer, Genomic Medicine Sweden and SciLifeLab, involving regulators, policymakers, payers, researchers, healthcare providers, patient advocates, and industry to drive the implementation of precision health in cancer care.

Testbed Sweden for Precision Health in Cancer is a system demonstrator of how to introduce concrete precision medicine activities into the Swedish healthcare system in a way that is sustainable and just.

Vision Zero Cancer and Testbed Sweden Precision Health Cancer organized two events in Almedalen 2023. Almedalen takes place each year in Sweden in the city of Visby at the island of Gotland and is the world's largest democratic meeting place for social issues.

PRIME-ROSE - A European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission. The project was approved by the European Commission om April 23 2023.

Join us for the EU Cancer Mission Day - Ireland, advancing the fight against cancer and improving lives.

We are excited to be part of the growing DLCT (DRUP-Like Clinical Trial) Community and are looking forward to start working on the implementation of precision medicine for all patients in Europe!